FDA Draft Guidance Updates Payor Communications Rules

FDA Draft Guidance Updates Payor Communications Rules

Key Takeaways

• The FDA issued draft guidance on June 2, 2026 on how drug and device companies may communicate health care economic information (HCEI) with payors and formulary committees.
• The 2026 draft guidance includes a statutory safe harbor for communications with payors, marking the most significant update to the framework.
• Device firms now have greater certainty regarding statutory protections previously available only to drug manufacturers.
• FDA guidance documents are generally not legally binding and do not establish enforceable responsibilities.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is medium for this topic. Track designations, submission types, and label or guidance shifts that could move timelines.

What Changed in the Draft Guidance

On June 2, 2026, the FDA issued draft guidance addressing manufacturer communications with payors, formulary committees, and similar entities regarding health care economic information. The document reflects statutory changes and provides interpretive direction on how drug and device companies may present pricing, value, and economic data to insurance companies and pharmacy benefit managers without triggering misbranding violations.

The most significant update is the inclusion of a statutory safe harbor for communications with payors. This safe harbor establishes conditions under which manufacturers can communicate about their products' economic value without regulatory jeopardy, provided the communications remain truthful and non-misleading.

A key benefit of the 2026 draft is that device manufacturers now have greater certainty regarding statutory protections that were previously available to drug firms. This alignment extends the regulatory safe harbor framework to medical device companies, reducing ambiguity about permissible communications in the device space.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low for this topic. Expect implications for pricing, access, and launch sequencing.

Statutory Foundation and Misbranding Standards

Under section 502(gg), drugs or devices are not considered misbranded if they engage in certain truthful and non-misleading communications to payors. This statutory provision forms the legal foundation for the safe harbor and permits manufacturers to discuss health care economic information without automatically triggering misbranding enforcement.

The draft guidance operationalizes this statutory language by offering manufacturers clarity on what constitutes permissible HCEI communications. By clarifying the boundaries, the guidance reduces compliance uncertainty for companies navigating payor relationships, particularly around formulary placement discussions and value-based contracting conversations.

IntelligenceStrategic Takeaways▾

The FDA issued draft guidance on June 2, 2026 on how drug and device companies may communicate health care economic information (HCEI) with payors and formulary committees. The 2026 draft guidance includes a statutory safe harbor for communications with payors , marking the most significant update to the framework. Device firms now have greater certainty regarding statutory protections previously available only to dr

Regulatory Status and Enforceability

FDA guidance documents are generally not legally binding and do not establish enforceable responsibilities on the FDA or the public. The draft guidance therefore serves as interpretive direction rather than a binding rule, reflecting the agency's current thinking on compliant manufacturer-payor communications.

Manufacturers should treat the draft guidance as an important reference for regulatory expectations, but the document's non-binding status means companies retain flexibility in how they structure their payor communications, provided they remain consistent with the underlying statutory safe harbor and truthfulness requirements.

Frequently Asked Questions